Getein Biotech Inc
SSE:603387
Getein Biotech Inc
SSE:603387
Price:
9.17
CNY
1.78%
Market Cap:
¥4.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Getein Biotech Inc
SSE:603387
|
CN |
|
H
|
Hellenic Exchanges Athens Stock Exchange SA
ATHEX:EXAE
|
GR |
|
Kinaxis Inc
TSX:KXS
|
CA |
|
Pnb Gilts Ltd
NSE:PNBGILTS
|
IN |
|
Avanos Medical Inc
NYSE:AVNS
|
US |
|
C&D Property Management Group Co Ltd
HKEX:2156
|
CN |
|
H
|
Harbin Sayyas Windows Co Ltd
SZSE:301227
|
CN |
|
Sumitomo Forestry Co Ltd
TSE:1911
|
JP |
|
Catella AB
STO:CAT B
|
SE |
|
Washington Hotel Corp
TSE:4691
|
JP |
|
Global Health Ltd
ASX:GLH
|
AU |
|
C
|
Cairn Homes PLC
LSE:CRN
|
IE |
|
Purplebricks Group PLC
LSE:PURP
|
UK |
Relative Value
The Relative Value of one
Getein Biotech Inc
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 9.17 CNY,
Getein Biotech Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Getein Biotech Inc Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
Getein Biotech Inc Competitors
Getein Biotech Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
|
Getein Biotech Inc
SSE:603387
|
4.7B CNY | 4.5 | 25.6 | 29.3 | 29.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6 | 87.5 | 14.5 | 20.2 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.9B USD | 109.6 | -1 710.6 | 15 890.6 | -1 794.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.6B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.2 | 35.2 | 11.6 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
